Business

Izotropic’s IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose

- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition - - Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 - - Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Iz

articleIzotropic Corp.September 23, 20255/company/izotropic-corporation/news/izotropic-izoview-breast-ct-first-120000521
Izotropic’s IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose

About this update from Izotropic Corp.

[{"type":"image","alt":"Izotropic","displaySize":"","headline":null,"caption":"Izotropic","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/342f0108283f64b41bf05ed2af94ca63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BChRXr4MzGGT2dgplDeEaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/342f0108283f64b41bf05ed2af94ca63","width":300,"height":83}},"lazy":false},{"type":"text","content":"- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition -","length":125,"tagName":"p"},{"type":"text","content":"- Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 -","length":134,"tagName":"p"},{"type":"text","content":"- Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization -","length":138,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the integration of a new patent-pending radiation dose personalization feature into its flagship device, the IzoView Breast CT Imaging System. This proprietary capability positions IzoView as the first breast CT system to offer real-time customized radiation dosing, using an integrated radiation-free optical pre-scan feature and proprietary software.","length":746,"tagName":"p"},{"type":"text","content":" Radiation Dose Personalization Engineered into IzoView Using Optical Pre-Scan","length":77,"tagName":"p"},{"type":"text","content":"The optical pre-scan system captures a radiation-free image of the breast and uses it to calculate a personalized radiation dose, custom to each patient’s breast size. The system uses this pre-scan data and dose reference models developed at UC Davis Medical Center (“UC Davis”), where breast CT technology was founded and advanced through over two decades ...

More updates from Izotropic Corp.

Izotropic CorporationBreast ImagingCT technologyThe Companyradiation dosedense breast tissueradiation dosesbreast cancersForward-Looking Statementsproprietary capabilitybreast sizeCompany